Praxis Precision Medicines, Inc.
Undisclosed program
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for Undisclosed program in its lead indication are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Topline EMERALD data in 4Q 2026”